title: Controlled reperfusion after myocardial ischemia in a canine model monitored by two-dimensional phosphorus 31 chemical shift spectroscopic imaging.
abstract: Phosphorus 31 magnetic resonance spectroscopy at 2 T was used to monitor high-energy phosphate metabolism over a 3-week period in a canine model of myocardial infarction and reperfusion. Twenty animals were divided into two groups: group 1 (n = 11) received intravenous nitroglycerin beginning at the onset of coronary occlusion; group 2 (n = 9) received a 105-minute infusion of superoxide dismutase (SOD) beginning at the onset of reperfusion. A metabolic protective effect was observed (vs controls) with both agents, manifested by a reduction in the degree of pH decline from baseline values and preservation of the adenosine triphosphate/total phosphate ratio during occlusion and reperfusion. Further, both treatments, compared with controls, produced a lower infarct/zone at risk ratio: controls, 1.5 +/- 1.2; nitroglycerin, 0.52 +/- 0.50; and SOD, 0.64 +/- 0.40. The technique of 31P magnetic resonance spectroscopy demonstrated its use for the noninvasive assessment of myocardial metabolism in response to therapeutic intervention.
authors.affiliation: Department of Medical Biophysics, University of Western Ontario, London, Canada.
authors.forename: C M
authors.initials: CM
authors.lastname: Campbell
authors.forename: G
authors.initials: G
authors.lastname: Wisenberg
authors.forename: J
authors.initials: J
authors.lastname: Sykes
authors.forename: R T
authors.initials: RT
authors.lastname: Thompson
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D003287:Contrast Media; D004285:Dogs; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use*; D019786:Gadolinium DTPA; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D015425:Myocardial Reperfusion / Q000379:methods*; D015428:Myocardial Reperfusion Injury / Q000175:diagnosis* / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism*; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D010710:Phosphates / Q000378:metabolism; D010725:Phosphocreatine / Q000378:metabolism; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D003287:Contrast Media; D016166:Free Radical Scavengers; D009942:Organometallic Compounds; D010710:Phosphates; D014665:Vasodilator Agents; D010725:Phosphocreatine; D004369:Pentetic Acid; D000255:Adenosine Triphosphate; D013482:Superoxide Dismutase; D005996:Nitroglycerin; D019786:Gadolinium DTPA